Neurona Therapeutics Stock

www.neuronatherapeutics.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $240.58MM

Neurona Therapeutics is a company that strives to develop clinical-stage biotherapeutic treatments for neurological disorders with a focus on advancing regenerative cell therapy candidates. The company researches allogeneic therapies that come from stem cells harvested from donors. Neurona's proprietary therapy NRTX-1001 aims to reverse the effects of Alzheimer’s disease and other nervous system disorders. Neurona Therapeutics was founded by Arnold Kriegstein and Cory R. Nicholasin in 2008 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Neurona Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Neurona Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Neurona Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Neurona Therapeutics investors also invested in these private companies

Ironfire Ventures
UC Investments
LYFE Capital
Schroders Capital
UCB Ventures
California Institute for Regenerative Medicine
Topspin Consumer Partners
Sphera Funds Management
Harvard University Endowment
Berkeley Frontier Fund
Willett Advisors


Management Team

Cory Nicholas Ph.D
Co-Founder & Chief Executive Officer
Arturo Álvarez-Buylla Ph.D
Co-Founder & Scientific Advisor
John Rubenstein Ph.D
Co-Founder & Scientific Advisor
Arnold Kriegstein Ph.D
Co-Founder & Scientific Advisor
James Stutz
Chief Financial Officer & Chief Business Officer
Gautam Banik Ph.D
Chief Technology Officer
Catherine Priest Ph.D
Chief Development Officer
David Blum MD
Chief Medical Officer

Board Members

David Goeddel Ph.D
The Column Group
Erica Whittaker Ph.D
UCB Ventures
Raymond Kelleher Ph.D
Cormorant Asset Management
Robert Tjian Ph.D
The Column Group
Timothy Kutzkey Ph.D
The Column Group

Neurona Therapeutics’ stock FAQs


Can you buy Neurona Therapeutics’ stock?

Neurona Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Neurona Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Neurona Therapeutics’ stock?

Yes, you can sell stock of a private company like Neurona Therapeutics. Forge can help you sell your Neurona Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Neurona Therapeutics’ stock price?

Neurona Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Neurona Therapeutics’ private market stock price with Forge Data.

What is Neurona Therapeutics’ stock ticker symbol?

Neurona Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Neurona Raises $120M, Buoyed by Early-Stage Data for Epilepsy Cell Therapy

Neurona Therapeutics on Thursday announced that it has secured $120 million in funding, which will help it advance its pipeline of investigational off-the-shelf cell therapies. The California-based biotech will use the money to advance its lead candidate NRTX-1001, a regenerative neural cell therapy candidate being assessed in a Phase I/II trial for drug-resistant mesial temporal lobe epilepsy (MTLE), the most common form of focal epilepsy that can trigger ongoing seizures despite medical treatment.

Neurona Therapeutics Raises $120M in Funding

Neurona Therapeutics, a San Francisco, CA-based clinical-stage biotherapeutics company, raised $120M in funding
Updated on: Jul 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.